Lv3
210 积分 2025-07-11 加入
Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
22天前
已完结
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
22天前
已完结
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
22天前
已完结
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia
22天前
已完结
Bispecific antibodies engage T cells for antitumor immunotherapy
22天前
已完结
Bispecific antibodies in acute lymphoblastic leukemia therapy
7个月前
已完结
Antipsychotic Drugs and Cognitive Function
8个月前
已完结
皖公网安备34019202002308
